ArticleFrontiers in medicine2026
Diagnostic value of PRIMARY score and a combined model with SUVmax in 18F-PSMA-1007 PET/CT for prostate cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the diagnostic value of the PRIMARY score in 18F-PSMA-1007 PET/CT for prostate cancer (PCa), to compare its diagnostic efficacy with maximum standardized uptake value (SUVmax), and explore the value of their combined model. Methods: A total of 180 patients with suspected prostate cancer were initially screened. After excluding 91 patients (70 with prior treatment, 16 without pathological confirmation, 3 with unclear pathological results, and 2 with poor image quality), 89 patients were finally enrolled. We retrospectively reviewed 89 patients with suspected PCa who underwent 18F-PSMA-1007 PET/CT from November 2023 to September 2025, including 61 with PCa and 28 with benign lesions. All patients underwent standard preoperative evaluation including PSA, digital rectal examination (DRE), ultrasound, or multiparametric MRI (mpMRI) before imaging. Prostate biopsy was performed within 2 weeks before or after PET/CT according to clinical indications. The SUVmax of the representative lesion was measured and the PRIMARY score was recorded. Intergroup differences were analyzed, optimal cutoff values were determined by ROC curve, and AUCs were compared by the DeLong test. Risk stratification was performed for clinically significant prostate cancer (csPCa), with focus on the combined diagnostic strategy for "gray-zone" lesions with PRIMARY score 4. Interobserver agreement was evaluated using the Kappa coefficient. Results: Age was comparable between the two groups ( Conclusion: In 18F-PSMA-1007 PET/CT, the PRIMARY score demonstrates comparable diagnostic efficacy to SUVmax with excellent reproducibility. The combined PRE model was superior to SUVmax alone, but not significantly different from PRIMARY score in this cohort, optimizing the stratification of PRIMARY score 4 "gray-zone" lesions. This approach effectively reduces false positives and provides a robust quantitative reference for biopsy decisions and individualized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.